Phase II clinical trial of interleukin-2, interferon-alpha and tegafur uracil therapy for advanced renal cell cancer

Phase II clinical trial of interleukin-2, interferon-alpha and tegafur uracil therapy for advanced renal cell cancer - IATRCC

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002222

Enrollment

Registered

2009-07-21

Start date

2009-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced renal cell cancer

Interventions

Interleulin-2, inteferon-alpha, tegafur uracil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)PS 0,1 or 2. (2)MSKCC risk classification; favorable or intermediate. (3)Histological confirmed renal cell carcinoma. Not includes sarcomatoid RCC as a major component. (4)Patients with pulmonary metastasis only, but includes those with no appearance of new lesion 4 weeks after surgical resection of extra-pulmonary metastasis. (5)No ischemic heart disease (6)Laboratory evaluation 1)Respiratory function; %VC >=80%, FEV1.0 >=70% 2)WBC>=4,000/mm2, platelet>=10,000/mm2 3)AST, ALT within normal range of each institute. total bil.<1.5mg/dl serum creatinine<2.0mg/dl, BUN<25mg/dl

Exclusion criteria

Exclusion criteria: (1)uncontrolled DM (2)ischemic heart disease (3)allergic reaction to IL-2 and/or IFN-alpha (4)auto-immune disease (5)patients having Shou-Sai-Kotou (special herbal drug) and/or steroids (6)depression (7)Investigator determines as unsuitable

Design outcomes

Primary

Measure	Time frame
anti-tumor response	—

Secondary

Measure	Time frame
Time to progression, duration of response, overall survival, servival at home, performance status	—

Countries

Japan

Contacts

Public ContactYoshihiko Tomita

Yamagata University Hospital Department of Urology

ytomita@med.id.yamagata-u.ac.jp023-628-5368

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026